Evaluating Resistant Hypertension Through Secondary Endocrine Screening Protocols

When triple-agent antihypertensive therapy fails to achieve blood pressure targets, systematic evaluation for primary aldosteronism becomes mandatory. Here is a high-yield diagnostic framework for clinical practice.

CLINICAL PROTOCOLS

9/4/20262 min read

Resistant hypertension affects nearly ten percent of adults presenting with elevated blood pressure, yet secondary etiologies frequently remain underdiagnosed. Failing to identify underlying hormonal imbalances prolongs target organ damage and increases cardiovascular morbidity over time. A structured, evidence-based protocol allows clinicians to screen efficiently before escalating empirical pharmacotherapy.

Initial Screening with Plasma Aldosterone to Renin Ratio

Screening for primary aldosteronism requires measuring morning plasma aldosterone concentration and plasma renin activity under standard baseline conditions. Clinicians must account for confounding medications such as mineralocorticoid receptor antagonists and direct renin inhibitors, which should be held or substituted when clinically safe.

An elevated ratio paired with a detectable aldosterone level warrants confirmation through oral or intravenous salt loading protocols. Rapid interpretation of these biomarker thresholds prevents unnecessary adrenal imaging while capturing high-risk patients early in the diagnostic pathway.

Confirmatory Testing and Adrenal Vein Sampling

Once biochemical hyperaldosteronism is confirmed, cross-sectional imaging with thin-slice computed tomography helps distinguish adrenal adenomas from bilateral adrenal hyperplasia. However, because non-functioning adrenal incidentalomas are common in older demographics, functional lateralization via adrenal vein sampling remains the gold standard prior to unilateral adrenalectomy.

Integrating this sequential workflow into routine clinical practice ensures that patients with surgical lesions undergo targeted resection while those with bilateral hyperplasia receive optimized medical management with targeted aldosterone antagonists.